Download Full Text (607 KB)

Document Type



Lung cancer is responsible for the most cancer-related deaths worldwide. While the implementation of low dose CT (LDCT) screening for high-risk individuals has been shown to improve outcomes and reduce mortality by 20%, there is still room for improvement in screening (de Koning et al, 2020). Multi-cancer early detection (MCED) tests aim to detect early-stage cancer with the goal of improving treatment outcomes. This technology combines plasma analysis for cell-free DNA and methylation patterns with artificial intelligence to detect malignancies and predict tumor origin sites. The purpose of this systemic literature review is to assess the rising potential of MCED for screening and early detection of lung cancer compared to LDCT. This review utilizes searches of PubMed and ClinicalKey. A total of 14 articles published over the last 20 years were included for analysis. Results indicate that MCED has a higher specificity than LDCT resulting in less false positives, however, the sensitivity of MCED for detecting lung cancer is not consistently high enough to replace LDCT. At this time, LDCT remains the gold standard for screening and early detection of lung cancer and should continue to be utilized in clinical practice. This study focused exclusively on lung cancer, but MCED has the capability to detect more than 50 types of cancer, many without a current screening. Further research should be conducted to explore the role of MCED as an adjunct to traditional cancer screenings.


Physician Assistant Studies

Degree Name

Master of Physician Assistant Studies (MPAS)

Date of Work


First Advisor

Staveteig, Mindy

Publication Date

Spring 2024


Medicine and Health Sciences

Blood Based Multi-Cancer Early Detection Tests in Lung Cancer Screening